Headquartered in Hong Kong, with offices in the US, an international asset management hub is actively investing in technology and healthcare. The firm focuses on early-stage and expansion opportunities, and can invest in both equity and debt. It typically participates in Series A to Series B rounds, with check sizes ranging from $1M to $50M. The firm primarily focuses on the US and Europe and is particularly interested in companies aiming to expand into Asian markets. The firm has partnerships with manufacturing, CRO, and distribution channels in China and is open to leveraging these resources for its portfolio companies. The firm is open to both leading and co-investing.
The firm primarily considers opportunities in therapeutics, medical devices, and healthtech. For therapeutics, the firm prefers companies/assets in the post-IND phase or those generating clinical data. For medical devices, the firm is open to all classes: for Class I devices, the firm prefers products that have already received approval; for Class II and Class III devices, it prefers mid to late-stage products with CE/FDA approval. For healthtech companies, the firm prefers those already generating revenue. The firm focuses on indications with large market potential, particularly in the US and China.
The firm does not have specific requirements for a company’s founding team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment